Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Eric Dein ericdeinmd
3 years 1 month ago
Ab0343. #ACR22 Severe non-adherence of HCQ associated with FLARES, DAMAGE and DEATH
7.3% had "severe non-adherence" by HCQ levels
Hazard ratio of flare 3.3, damage 4.26, and death 5.4
Not surprising, but very useful for pt discussion
Checking HCQ levels are helpful!
@Rheumnow https://t.co/S7P9oTPRGJ
TheDaoIndex KDAO2011
3 years 1 month ago
Study showing Evusheld can protect our patients who are immunosuppressed; it saved alot of live. One of Dr. C Langford's pick for #YearinReview @rheumnow #ACR22 https://t.co/6ekWvA6Ruw
Aurelie Najm AurelieRheumo
3 years 1 month ago
ACR Year in review J. Varga
What drives TNF superproduction in RA?
Study mice 🐁 model grafted w/ human synovial tissue suggests
important role of mitochondrial stress through aspartate deficiency
A potential new therapeutic target 🎯 RA?
@RheumNow #ACR22 #ACRyearinreview https://t.co/lKrOn05sFp
Patricia Harkins DrTrishHarkins
3 years 1 month ago
Was delighted to be a (very) small part of the fantastic work by the covid GRA getting a special mention by Dr Langford at yr in review #ACR22 @RheumNow
Congrats @RichardPAConway @EBRheum @jeffsparks @SattuiSEMD @rheum_cat 🎉 https://t.co/W0n7rW9pma
TheDaoIndex KDAO2011
3 years 1 month ago
Dr. C Langford's pick for #YearinReview; she is impressed with the novel mechanistic approaches to #SLE @rheumnow #ACR22. https://t.co/5GrtMYYZSv
Bella Mehta bella_mehta
3 years 1 month ago
Role of acquired mutations in #gout
Risk factor for gout CHIP?
Individuals with CHIP are more likely to developed acute episodes of gouty episodes
More IL-1B in cells with somatic mutations like CHIP
@rheumnow #ACR22 #yearinreview https://t.co/k3VeZuTCln
sheila RHEUMarampa
3 years 1 month ago
Tissue-resident memory T cells (Trm):
☝️Do not recirculate by blood or lymphatics
☝️Can drive recurrent inflammation
☝️Fixed-drug eruption is an example
CD8Trm - abundant in late stage non-inflamed RA synovium
#ACR22 @RheumNow #yearinreview #RheumTwitter https://t.co/LfTI0LamkN
Janet Pope Janetbirdope
3 years 1 month ago
CHIP- need to know! Somatic mutations fondly known as CHIP - not the salty ones. Clonal hematopoeisis of uncertain significance. Older Pts getting somatic mutations account for more CVS, malignancies , one change in TET2 increased gout #ACR2022 @RheumNow John Barga Yr in Review https://t.co/6bnqnkDFpL
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR2022 Year in Review. Dr Varga highlighted work by @GeorgeTsokos. In #lupus mice, adding CD38-i in a CD8+ T cell–targeted manner improved effector function, reversed the defects and improved viral clearance. CD38 as a target could reduce infection in SLE @rheumnow https://t.co/XlmvysjkDP
Eric Dein ericdeinmd
3 years 1 month ago
Ab0344 #ACR22
CKD2+ a/w incr HCQ levels by 149 ng/mL vs CKD1
400 mg/d dose: incr HCQ levels by 448 ng/mL vs 200
Incr body wt by 15 kg -> decr HCQ levels by 82 ng/mL
Social determinants didn't effect data
>750ng/mL and >1000 predicted of 75% decr flare risk
@Rheumnow #ACRBest https://t.co/p21rqnO4ym
Akhil Sood MD AkhilSoodMD
3 years 1 month ago
Abstr 0373 created a scoring system to predict outcomes in SpA pts w/ uveitis
- Poor outcomes seen among smoking hx, females, +HLAB27, axial & peripheral involvement, high disease activity, inflammation, and b/l eye involvement
https://t.co/mGAn0Eel1O
@RheumNow #ACR22 https://t.co/qtJsavtG9z
Dr. John Cush RheumNow
3 years 1 month ago
New 2022 EULAR Recommendations for the Management of RA
The updated '22 EULAR recommendations for the mgmt of RA were initially presented at EULAR '22, and are now in press delineating the most recent developments and perspectives in RA treatment.
https://t.co/xnpOUnpgvy https://t.co/OWcRq7nZ57
Mike Putman EBRheum
3 years 1 month ago
Talking a lot about CAR-T these days! Upcoming @Figure1 newsletter, blog post @RheumNow, and interview w/@MaxKonigMD comping soon!
I'm actually skeptical of this in SLE; are B cells really the answer?
w/better targeting & dx selection, this could be game changing
#ACR22 https://t.co/Z6t99ZIeMy
Aurelie Najm AurelieRheumo
3 years 1 month ago
A group of older patients w/ multimorbidity (5+) drives higher mortality risk in RA.
Crowson et al. stratification 4 clusters. Each cluster = different outcome, younger cluster w/ few comorbidities = no > mortality
https://t.co/IYccicjcyy
Abstr #0246 #ACR22 @Rheumnow #ACRBest https://t.co/ee9sgG3g0l
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
2022 has been a great year for development of novel therapies in Phase 2 RCTs in #lupus as highlighted by Dr Langford #ACR22 Year In Review. I'd add Deucravacitinib to those lists. Look forward to Phase 3 results soon @RheumNow https://t.co/yH25KFDGdd
Poster Hall